Global Breast Implants Revenue Was Valued At 1359.89 M USD In 2017
Thursday, 10 Jan, 2019
Two of the key drivers for this market are the increasing beauty consciousness among consumers and the decreasing procedural costs. A rapidly aging baby boomer population with an increased focus on their physical appearance coupled with wider availability of highly cohesive silicone breast implants is factors likely to boost the growth of the global breast implants market during the forecast period. People in countries like Brazil, the US, South Korea, and Venezuela pay a lot of attention to physical appearances, grooming, and personal care, which puts these countries at the top of the leaderboard in the market. Also, a large number of women are opting for breast implants during their reproductive ages and this has resulted in more number of breast augmentation procedures globally. Other prominent growth drivers are a growing prevalence of breast cancer and the availability of an expanded product line with premium pricing leading to greater sales.
Rise in global disposable income and growth in reimbursement rates for reconstructive procedures are expected to propel the market growth for breast implant during the forecast period. In addition, availability of premium-priced products, expansion of product portfolio, and increase in prevalence of breast cancer are factors driving the global market growth for breast implant. As per data released by the World Health Organization (WHO), in 2012, 1.7 million women were diagnosed with breast cancer, leading to approximately 522,000 deaths during the same year. Hence, increase in breast cancer prevalence is a major factor contributing to revenue growth of the breast implant market across the globe. However, risk of developing serious complications and lack of skilled nursing facilities in developing regions may hamper the market share. Large amount of documented evidences supporting the possibility of developing breast cancer after getting breast implants is one of the prime reasons hampering the growth of the market. In 2011, FDA indicated possible association between breast implants (saline and silicone) and anaplastic large-cell lymphoma (ALCL). Anaplastic large-cell lymphoma is a rare type of non-Hodgkin’s lymphoma (NHL), characterized by abnormal growth of T-lymphocytes. According to the National Cancer Institute, the disease affects 1 in 500,000 women globally. However, in the U.S., ALCL affects 3 in 100 million women who have undergone breast implants surgery.
Additionally, the cost of breast implant surgeries has dropped considerably over the past few years. This can be attributed to the high level of competition among plastic surgeons and the growing number of cosmetic surgery clinics, where reduced prices give them a market edge.
According to study, the Global revenue of Breast Implants was valued at 1359.89 M USD in 2017, and is forecast to reach 2264.4 M USD by the end of 2023.
Allergan accounted for 29.377% of the global Breast Implants revenue market share in 2017. Followed players, Mentor Worldwide accounted for 22.992%%, GC Aesthetics accounted for 5.268%.
Global giant manufactures mainly distributed in America and Europe. They have unshakable status in this field. The key product markets locate at America and Europe. North America takes the consumption market share of 48.22% in 2017, Europe followed by with 19.83% in 2017.
The market is not only influenced by the price, but also influenced by the product performance. The leading companies own the advantages on better performance, more abundant product’s types, better technical and impeccable after-sales service. Consequently, they take the majority of the market share of high-end market.
Looking to the future years, prices gap between different brands will go narrowing. Similarly, there will be fluctuation in gross margin.
Despite the presence of competition problems, due to the global recovery trend is slightly, investors are still optimistic about this area; the future will still have more new investment enter the field.